DM
Therapeutic Areas
NeoGenomics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RaDaR® ST | Minimal Residual Disease (MRD) detection and recurrence monitoring across solid tumors | Commercial |
| NEO | PanTracer™ Pro | Comprehensive genomic profiling for personalized therapy selection in oncology | Commercial |
| Portfolio of >500 Tests | Various solid tumors and hematologic cancers (e.g., lung, breast, leukemia) | Commercial |
Leadership Team at NeoGenomics
TZ
Tony Zook
Chief Executive Officer
JS
Jeff Sherman
Chief Financial Officer
EF
Elizabeth Floegel
Chief Digital and Information Officer
AO
Alicia Olivo, Esq.
Executive Vice President, General Counsel & Business Development
WS
Warren Stone
President and Chief Operating Officer
BE
Beth Eastland
EVP of Enterprise Sales
GP
Gary Passman
Chief Culture Officer
KS
Kareem Saad
Head of Strategy and Transformation
AL
Andrew Lukowiak, PhD
Chief Innovation Officer
NM
Nathan Montgomery, MD, PhD
Vice President, Medical Services